0
Neurocognitive Disorders in DSM-5
Dan Blazer, M.D., Ph.D.
China’s New Mental Health Law: Reframing Involuntary Treatment
Michael R. Phillips, M.D., M.P.H.; Hanhui Chen, M.D., Ph.D.; Kate Diesfeld, J.D.; Bin Xie, M.D.; Hui G. Cheng, Ph.D.; Graham Mellsop, M.D.; Xiehe Liu, M.D.
CME   “Selfish Spermatogonial Selection”: A Novel Mechanism for the Association Between Advanced Paternal Age and Neurodevelopmental Disorders
Anne Goriely, Ph.D.; John J. McGrath, M.D., Ph.D.; Christina M. Hultman, Ph.D.; Andrew O.M. Wilkie, D.M., F.R.C.P.; Dolores Malaspina, M.D., M.S.P.H.
Relapse Duration, Treatment Intensity, and Brain Tissue Loss in Schizophrenia: A Prospective Longitudinal MRI Study
Nancy C. Andreasen, M.D., Ph.D.; Dawei Liu, Ph.D.; Steven Ziebell, B.A.; Anvi Vora, M.D.; Beng-Choon Ho, M.D.
Decreased Cortical Representation of Genital Somatosensory Field After Childhood Sexual Abuse
Christine M. Heim, Ph.D.; Helen S. Mayberg, M.D.; Tanja Mletzko, M.S.; Charles B. Nemeroff, M.D., Ph.D.; Jens C. Pruessner, Ph.D.
Maintenance Cognitive-Behavioral Therapy and Manualized Psychoeducation in the Treatment of Recurrent Depression: A Multicenter Prospective Randomized Controlled Trial
Ulrich Stangier, Ph.D.; Christine Hilling, M.Sc.; Thomas Heidenreich, Ph.D.; Anne Katrin Risch, Ph.D.; Arnd Barocka, M.D.; Ralf Schlösser, M.D.; Kai Kronfeld, Ph.D.; Christian Ruckes, M.Sc.; Hartmut Berger, M.D.; Joachim Röschke, M.D.; Florian Weck, Ph.D.; Stephan Volk, M.D.; Martin Hambrecht, M.D.; Richard Serfling, M.D.; Ralf Erkwoh, M.D.; Aglaja Stirn, M.D.; Thomas Sobanski, M.D.; Martin Hautzinger, Ph.D.
Increase in Work Productivity of Depressed Individuals With Improvement in Depressive Symptom Severity
Madhukar H. Trivedi, M.D.; David W. Morris, Ph.D.; Stephen R. Wisniewski, Ph.D.; Ira Lesser, M.D.; Andrew A. Nierenberg, M.D.; Ella Daly, M.B., M.R.C.Psych.; Benji T. Kurian, M.D., M.P.H.; Bradley N. Gaynes, M.D.; G.K. Balasubramani, Ph.D.; A. John Rush, M.D.
Evaluation of the FDA Warning Against Prescribing Citalopram at Doses Exceeding 40 mg
Kara Zivin, Ph.D.; Paul N. Pfeiffer, M.D.; Amy S.B. Bohnert, Ph.D.; Dara Ganoczy, M.P.H.; Frederic C. Blow, Ph.D.; Brahmajee K. Nallamothu, M.D.; Helen C. Kales, M.D.
Moderators of Outcome in Late-Life Depression: A Patient-Level Meta-Analysis
J. Craig Nelson, M.D.; Kevin L. Delucchi, Ph.D.; Lon S. Schneider, M.D.
Transitions in Illicit Drug Use Status Over 3 Years: A Prospective Analysis of a General Population Sample
Wilson M. Compton, M.D., M.P.E.; Deborah A. Dawson, Ph.D.; Kevin P. Conway, Ph.D.; Marc Brodsky, M.S.; Bridget F. Grant, Ph.D.
CME   Cognitive Experiences Reported by Patients With Borderline Personality Disorder and Axis II Comparison Subjects: A 16-Year Prospective Follow-Up Study
Mary C. Zanarini, Ed.D.; Frances R. Frankenburg, M.D.; Michelle M. Wedig, Ph.D.; Garrett M. Fitzmaurice, Sc.D.
Response to Barglow Letter
Darrel A. Regier, M.D., M.P.H.; Matthew J. Friedman, M.D., Ph.D.; Helena C. Kraemer, Ph.D.; William E. Narrow, M.D., M.P.H.; David J. Kupfer, M.D.
Sustained Weight Loss After Treatment With a Glucagon-Like Peptide-1 Receptor Agonist in an Obese Patient With Schizophrenia and Type 2 Diabetes
Pelle L. Ishøy, M.D.; Filip K. Knop, M.D., Ph.D.; Tina Vilsbøll, M.D., D.M.SC.; Birte Y. Glenthøj, M.D., D.M.SC.; Bjørn H. Ebdrup, M.D., Ph.D.
Monthly Injectable Naltrexone for Pathological Gambling
Gihyun Yoon, M.D.; Suck Won Kim, M.D.
Genome-Wide Association Study of Cognitive Decline in Schizophrenia
Ryota Hashimoto, M.D., Ph.D.; Masashi Ikeda, M.D., Ph.D.; Kazutaka Ohi, M.D., Ph.D.; Yuka Yasuda, M.D., Ph.D.; Hidenaga Yamamori, M.D., Ph.D.; Motoyuki Fukumoto, M.D.; Satomi Umeda-Yano, Ph.D.; Dwight Dickinson, Ph.D.; Branko Aleksic, M.D., Ph.D.; Masao Iwase, M.D., Ph.D.; Hiroaki Kazui, M.D., Ph.D.; Norio Ozaki, M.D., Ph.D.; Daniel R. Weinberger, M.D.; Nakao Iwata, M.D., Ph.D.; Masatoshi Takeda, M.D., Ph.D.